{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:57:36Z","timestamp":1791107856874,"version":"4.1.0"},"reference-count":48,"publisher":"Microbiology Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11,1]]},"abstract":"<jats:p>Hepatitis C virus (HCV) is a major cause of liver disease worldwide and there is a pressing need for the development of a preventative vaccine as well as new treatments. It was recently demonstrated that the mouse monoclonal antibody (mAb) AP33 potently neutralizes infectivity of HCV pseudoparticles (HCVpp) carrying E1E2 envelopes representative of all of the major genotypes of HCV. This study determined the prevalence of human serum antibodies reactive to the region of HCV E2 recognized by AP33. Antibodies recognizing this region were present in less than 2.5\u200a% of sera obtained from individuals with chronic HCV infection. A similar prevalence was found in a smaller cohort of individuals who had experienced an acute infection, suggesting that AP33-like antibodies do not play a major role in natural clearance of HCV infection. Sera exhibited different patterns of reactivity to a panel of peptides representing circulating variants, highlighting the presence of distinct epitopes in this region. Only two sera contained antibodies that could recognize a specific AP33-reactive peptide mimotope. AP33-like antibodies made a measurable contribution to the ability of these sera to inhibit E2\u2013CD81 interaction, but not to the overall neutralization of cell entry. Together, these data show that antibodies to the AP33 epitope are not commonly generated during natural infection and that generation of such antibodies via vaccination may require modified immunogens to focus the generation of specific antibodies. Importantly, individuals harbouring AP33-like antibodies are an important potential source of human mAbs for future therapeutic development.<\/jats:p>","DOI":"10.1099\/vir.0.83065-0","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T19:27:59Z","timestamp":1192735679000},"page":"2991-3001","source":"Crossref","is-referenced-by-count":70,"title":["Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33"],"prefix":"10.1099","volume":"88","author":[{"given":"Alexander W.","family":"Tarr","sequence":"first","affiliation":[{"name":"The Institute of Infection, Immunity and Inflammation and Division of Microbiology, The University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania M.","family":"Owsianka","sequence":"additional","affiliation":[{"name":"MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanya","family":"Jayaraj","sequence":"additional","affiliation":[{"name":"The Institute of Infection, Immunity and Inflammation and Division of Microbiology, The University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J. P.","family":"Brown","sequence":"additional","affiliation":[{"name":"The Institute of Infection, Immunity and Inflammation and Division of Microbiology, The University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hickling","sequence":"additional","affiliation":[{"name":"The Institute of Infection, Immunity and Inflammation and Division of Microbiology, The University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William L.","family":"Irving","sequence":"additional","affiliation":[{"name":"The Institute of Infection, Immunity and Inflammation and Division of Microbiology, The University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind H.","family":"Patel","sequence":"additional","affiliation":[{"name":"MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street, Glasgow G11 5JR, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan K.","family":"Ball","sequence":"additional","affiliation":[{"name":"The Institute of Infection, Immunity and Inflammation and Division of Microbiology, The University of Nottingham, Queen's Medical Centre, Nottingham NG7 2UH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1099\/0022-1317-81-10-2451","article-title":"Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81","volume":"81","author":"Allander","year":"2000","journal-title":"J Gen Virol"},{"key":"R2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-2000-9505","article-title":"Recovery, persistence and sequelae in hepatitis C infection: a perspective on long-term outcome","volume":"20","author":"Alter","year":"2000","journal-title":"Semin Liver Dis"},{"key":"R3","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1128\/JVI.76.14.6919-6928.2002","article-title":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles","volume":"76","author":"Andre","year":"2002","journal-title":"J Virol"},{"key":"R4","first-page":"35","article-title":"Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp","volume":"6","year":"1999","journal-title":"Belgium. J Viral Hepat"},{"key":"R5","doi-asserted-by":"crossref","first-page":"14199","DOI":"10.1073\/pnas.2335981100","article-title":"In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes","volume":"100","author":"Bartosch","year":"2003a","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1084\/jem.20021756","article-title":"Infectious hepatitis C virus pseudo-particles containing functional E1\u2013E2 envelope protein complexes","volume":"197","author":"Bartosch","year":"2003b","journal-title":"J Exp Med"},{"key":"R7","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1128\/JVI.79.13.8217-8229.2005","article-title":"An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies","volume":"79","author":"Bartosch","year":"2005","journal-title":"J Virol"},{"key":"R8","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1099\/vir.0.80957-0","article-title":"Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection","volume":"86","author":"Brown","year":"2005","journal-title":"J Gen Virol"},{"key":"R9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1099\/vir.0.82357-0","article-title":"Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes","volume":"88","author":"Brown","year":"2007","journal-title":"J Gen Virol"},{"key":"R10","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.1128\/JVI.75.20.9986-9990.2001","article-title":"Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries","volume":"75","author":"Bugli","year":"2001","journal-title":"J Virol"},{"key":"R11","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ni0304-233","article-title":"HIV vaccine design and the neutralizing antibody problem","volume":"5","author":"Burton","year":"2004","journal-title":"Nat Immunol"},{"key":"R12","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.1128\/JVI.76.15.7672-7682.2002","article-title":"Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles","volume":"76","author":"Clayton","year":"2002","journal-title":"J Virol"},{"key":"R13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3109\/00365529609094740","article-title":"Hepatitis C virus: biological and clinical consequences of genetic heterogeneity","volume":"218","author":"Cooreman","year":"1996","journal-title":"Scand J Gastroenterol Suppl"},{"key":"R14","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1128\/JVI.64.8.3804-3809.1990","article-title":"Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine","volume":"64","author":"Dietzschold","year":"1990","journal-title":"J Virol"},{"key":"R15","doi-asserted-by":"crossref","first-page":"18285","DOI":"10.1074\/jbc.M602706200","article-title":"High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI","volume":"281","author":"Dreux","year":"2006","journal-title":"J Biol Chem"},{"key":"R16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/intimm\/11.4.577","article-title":"Identification of antigenic escape variants in an immunodominant epitope of hepatitis C virus","volume":"11","author":"Eckels","year":"1999","journal-title":"Int Immunol"},{"key":"R17","doi-asserted-by":"crossref","first-page":"15394","DOI":"10.1073\/pnas.93.26.15394","article-title":"Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein","volume":"93","author":"Farci","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18","doi-asserted-by":"crossref","first-page":"6235","DOI":"10.1128\/JVI.73.8.6235-6244.1999","article-title":"Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81","volume":"73","author":"Flint","year":"1999","journal-title":"J Virol"},{"key":"R19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/viro.1998.9202","article-title":"Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties","volume":"249","author":"Habersetzer","year":"1998","journal-title":"Virology"},{"key":"R20","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.74.22.10407-10416.2000","article-title":"Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes","volume":"74","author":"Hadlock","year":"2000","journal-title":"J Virol"},{"key":"R21","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1128\/JVI.00127-07","article-title":"The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein","volume":"81","author":"Helle","year":"2007","journal-title":"J Virol"},{"key":"R22","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1073\/pnas.0832180100","article-title":"Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles","volume":"100","author":"Hsu","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/hep.510280429","article-title":"High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C","volume":"28","author":"Ishii","year":"1998","journal-title":"Hepatology"},{"key":"R24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/(SICI)1096-9071(199701)51:1<67::AID-JMV11>3.0.CO;2-1","article-title":"Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma","volume":"51","author":"Jackson","year":"1997","journal-title":"J Med Virol"},{"key":"R25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/hep.20542","article-title":"Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus","volume":"41","author":"Lavillette","year":"2005","journal-title":"Hepatology"},{"key":"R26","doi-asserted-by":"crossref","first-page":"10149","DOI":"10.1073\/pnas.0403519101","article-title":"Neutralizing antibody response during acute and chronic hepatitis C virus infection","volume":"101","author":"Logvinoff","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1046\/j.1365-2141.1996.02343.x","article-title":"The natural history of chronic hepatitis C in haemophiliacs","volume":"94","author":"Makris","year":"1996","journal-title":"Br J Haematol"},{"key":"R28","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1099\/0022-1317-69-7-1531","article-title":"The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1","volume":"69","author":"McGeoch","year":"1988","journal-title":"J Gen Virol"},{"key":"R29","first-page":"3858","article-title":"Growth of human hepatoma cells lines with differentiated functions in chemically defined medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res"},{"key":"R30","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1099\/0022-1317-82-8-1877","article-title":"Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2","volume":"82","author":"Owsianka","year":"2001","journal-title":"J Gen Virol"},{"key":"R31","doi-asserted-by":"crossref","first-page":"11095","DOI":"10.1128\/JVI.79.17.11095-11104.2005","article-title":"Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein","volume":"79","author":"Owsianka","year":"2005","journal-title":"J Virol"},{"key":"R32","doi-asserted-by":"crossref","first-page":"8695","DOI":"10.1128\/JVI.00271-06","article-title":"Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding","volume":"80","author":"Owsianka","year":"2006","journal-title":"J Virol"},{"key":"R33","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1099\/0022-1317-81-12-2873","article-title":"Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding","volume":"81","author":"Patel","year":"2000","journal-title":"J Gen Virol"},{"key":"R34","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1073\/pnas.0607026104","article-title":"Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C","volume":"104","author":"Pestka","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R35","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1073\/pnas.93.5.1759","article-title":"A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells","volume":"93","author":"Rosa","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/jhep.2000.19789","article-title":"Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review","volume":"32","author":"Shouval","year":"2000","journal-title":"Hepatology"},{"key":"R37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1099\/0022-1317-82-4-693","article-title":"The origin and evolution of hepatitis viruses in humans","volume":"82","author":"Simmonds","year":"2001","journal-title":"J Gen Virol"},{"key":"R38","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1128\/JCM.31.6.1493-1503.1993","article-title":"Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3","volume":"31","author":"Simmonds","year":"1993","journal-title":"J Clin Microbiol"},{"key":"R39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virol.2003.10.008","article-title":"HCV E2 glycoprotein: mutagenesis of N -linked glycosylation sites and its effects on E2 expression and processing","volume":"319","author":"Slater-Handshy","year":"2004","journal-title":"Virology"},{"key":"R40","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.21088","article-title":"Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33","volume":"43","author":"Tarr","year":"2006","journal-title":"Hepatology"},{"key":"R41","first-page":"177","article-title":"Cloning, expression and functional analysis of patient-derived hepatitis C virus glycoproteins","volume-title":"In Glycovirology Protocols","author":"Tarr","year":"2007"},{"key":"R42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1006\/viro.2002.1463","article-title":"Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding","volume":"298","author":"Triyatni","year":"2002","journal-title":"Virology"},{"key":"R43","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1128\/JVI.69.2.773-778.1995","article-title":"Sequence evolution of the hypervariable region in the putative envelope region E2\/NS1 of hepatitis C virus is correlated with specific humoral immune responses","volume":"69","author":"van Doorn","year":"1995","journal-title":"J Virol"},{"key":"R44","doi-asserted-by":"crossref","first-page":"7793","DOI":"10.1074\/jbc.M411600200","article-title":"High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I","volume":"280","author":"Voisset","year":"2005","journal-title":"J Biol Chem"},{"key":"R45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"R46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K","article-title":"A model for the hepatitis C virus envelope glycoprotein E2","volume":"40","author":"Yagnik","year":"2000","journal-title":"Proteins"},{"key":"R47","doi-asserted-by":"crossref","first-page":"8449","DOI":"10.1073\/pnas.0703039104","article-title":"Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R48","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0198-8859(02)00430-5","article-title":"Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+\/tetramer positive CTL","volume":"63","author":"Zhu","year":"2002","journal-title":"Hum Immunol"}],"container-title":["Journal of General Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.83065-0?crawler=true","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T22:23:40Z","timestamp":1603751020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jgv\/10.1099\/vir.0.83065-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,1]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2007,11,1]]}},"URL":"https:\/\/doi.org\/10.1099\/vir.0.83065-0","relation":{},"ISSN":["0022-1317","1465-2099"],"issn-type":[{"value":"0022-1317","type":"print"},{"value":"1465-2099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,11,1]]}}}